Reni Benjamin
Stock Analyst at Citizens
(1.27)
# 3,697
Out of 5,134 analysts
162
Total ratings
35.29%
Success rate
-16.6%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Upgrades: Market Outperform | $5 | $2.16 | +131.48% | 9 | Jan 9, 2026 | |
| CMPX Compass Therapeutics | Initiates: Market Outperform | $10 | $6.39 | +56.49% | 1 | Dec 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $10 → $12 | $5.23 | +129.45% | 15 | Oct 31, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $78.77 | - | 10 | May 15, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.29 | +587.05% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.14 | +608.22% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $101.16 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $7.04 | - | 5 | Mar 7, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $0.66 | +507.26% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.68 | +138.10% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.15 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.53 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $15.95 | -37.30% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $23 | $16.64 | +38.26% | 11 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $3.85 | +29.87% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $8.48 | +230.19% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.59 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $15.68 | +155.10% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.62 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $2.11 | +89.57% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $9.34 | -14.35% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $46.06 | +30.28% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $9.44 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $143.12 | +120.10% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $70.53 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $245.41 | +7.98% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $3.41 | +398.53% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $8.04 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.70 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $29.06 | -58.71% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $20.60 | - | 1 | Nov 15, 2017 |
Allogene Therapeutics
Jan 9, 2026
Upgrades: Market Outperform
Price Target: $5
Current: $2.16
Upside: +131.48%
Compass Therapeutics
Dec 3, 2025
Initiates: Market Outperform
Price Target: $10
Current: $6.39
Upside: +56.49%
Bicycle Therapeutics
Oct 31, 2025
Maintains: Market Outperform
Price Target: $10 → $12
Current: $5.23
Upside: +129.45%
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $78.77
Upside: -
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.29
Upside: +587.05%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.14
Upside: +608.22%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $101.16
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $7.04
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $0.66
Upside: +507.26%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.68
Upside: +138.10%
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.15
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $6.53
Upside: -
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $15.95
Upside: -37.30%
Jan 20, 2026
Upgrades: Market Outperform
Price Target: $23
Current: $16.64
Upside: +38.26%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $3.85
Upside: +29.87%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $8.48
Upside: +230.19%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.59
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $15.68
Upside: +155.10%
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.62
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $2.11
Upside: +89.57%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $9.34
Upside: -14.35%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $46.06
Upside: +30.28%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $9.44
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $143.12
Upside: +120.10%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $70.53
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $245.41
Upside: +7.98%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $3.41
Upside: +398.53%
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $8.04
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.70
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $29.06
Upside: -58.71%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $20.60
Upside: -